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Cost-effectivenessAim: Coronary angiography is indicated inmanypatientswith knownor suspected angina for the investigation of
coronary artery disease (CAD). However, up to half of patients with symptoms of ischaemia have no obstructive
coronary arteries (INOCA). This large subgroup includes patients with suspected microvascular angina (MVA)
and/or vasospastic angina (VSA). Clinical guidelines relating to the management of patients with INOCA are lim-
ited. Uncertainty regarding the diagnosis of patients with INOCA presents a health economic challenge, both in
terms of healthcare resource utilisation and of quality-of-life impact on patients.
Methods: A cost-effectiveness analysis of the introduction of stratifiedmedicine into the invasivemanagement of
INOCA, based on clinical and resource-use data obtained in the CorMicA trial, from a UKNHS perspective. The in-
tervention included an invasive diagnostic procedure (IDP) of coronary vascular function during coronary angi-
ography to define clinical endotypes to targetwith linkedmedical therapy. Outcomes of interestweremean total
cost andQALY gain between treatment groups, and the incremental cost-effectiveness ratio.Weundertook prob-
abilistic sensitivity and scenario analyses.
Results: The incremental cost per QALY gained at 12 months was £4500 (£2937, £33264). Compared with a
willingness-to-pay (WTP) threshold of £20,000 per QALY, the use of the IDP test is cost-effective. At this WTP
threshold there is a 96% probability of the IDP being cost-effective, based on the uncertainty described by boot-
strap analysis.
Conclusions: The burden of INOCA, particularly in women, is known to be significant. These findings provided
new evidence to inform this unmet clinical need.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Coronary angiography is routinely performed in patients with
suspected angina. Approximately four million elective coronary an-
giograms are performed each year in Europe and the United StatesHealth Technology Assessment
ens, Glasgow G12 8RZ, United
ation Glasgow Cardiovascuar
ciences, University of Glasgow,
gie), colin.berry@glasgow.ac.uk
.V. This is an open access article und[1,2]. However, up to half of patients with signs and/or symptoms
of ischaemia have no obstructive coronary arteries (INOCA) pre-
senting a diagnostic and therapeutic challenge for clinicians [2].
This large subgroup includes patients with suspected microvascular
angina (MVA) and/or vasospastic angina (VSA) [3]. Coronary angi-
ography is insensitive in visualising the micro-vessels [4]. Coronary
angiography is also insensitive for coronary reactivity and a pa-
tient's susceptibility to vasospasm. The rationale for adjunctive cor-
onary vascular function testing, in the form of an interventional
diagnostic procedure (IDP) is as follows. Firstly, coronary angiogra-
phy does not exclude a disorder of coronary vascular function, such
as those relating to vasomotion or microcirculation [3]. Secondly,
adjunctive coronary testing allows for the stratification of thiser the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cause discrimination between microvascular angina, vasospastic
angina, both, or neither, allows for specific and distinct treatment
regimes. Finally, adjustive coronary function testing provides both
patients and their physicians with prognostic information. Clinical
guidelines relating to the management of patients with INOCA are
limited by a lack of randomised controlled trials [5].
The uncertainty regarding the diagnosis of patients with INOCA
presents a health economic challenge, both in terms of healthcare re-
source utilisation and of quality-of-life impact on patients. Patients
with INOCA who remain undiagnosed are liable to re-present at pri-
mary or secondary care. This may result in additional GP consulta-
tions, outpatient cardiologist visits, diagnostic tests and repeat
coronary angiography.
The British Heart Foundation (BHF) Coronary Microvascular Angina
(CorMicA) trial was a randomised, controlled, developmental clinical
trial of stratified medicine in patients with known or suspected angina
undergoing clinically-indicated coronary angiography in the National
Health Service.
The CorMicA study design and main trial results have been de-
scribed in detail elsewhere [3,6,7]. In summary, 391 patients with an-
gina undergoing invasive coronary angiography (standard care) were
recruited between November 2016 and December 2017. 151 patients
without angiographically obstructive CAD were randomised to either
the intervention group (standard care, plus IDP-guided stratified med-
ical therapy and cardiac rehabilitation) (n = 76) or control group
(standard care, plus medical therapy and cardiac rehabilitation)
(n = 75). The IDP consisted of guidewire-based assessment of coro-
nary flow reserve, index of microcirculatory resistance, fractional
flow reserve, followed by vasoreactivity testing with acetylcholine.
Following the IDP, clinicians were able to update their diagnosis, if in-
dicated, based on this additional information, and to tailor patient
medical therapy and cardiac rehabilitation accordingly. The interven-
tion resulted in a mean improvement of 13.6 units in the Seattle An-
gina Questionnaire summary score (primary outcome) at 12 months
(95% CI: 7.3–19.9; p < 0.001).
The aim of this study was to undertake a cost-effectiveness analysis
of the BHF CorMicA trial, using resource use and quality of life data from
the trial, to estimate the potential cost-effectiveness of the use of the IDP
among INOCA patients undergoing routine coronary angiography.2. Methods
2.1. Overview
An economic evaluation was undertaken using clinical and resource
use data obtained from the CorMicA feasibility trial and from the wider
literature. We employed the standard methodology for an economic
evaluation alongside a clinical trial [8]. A conceptual model was de-
signed and presented to illustrate the patient pathway and to facilitate
interpretation of the trial data.2.2. Study perspective
The economic evaluation was undertaken from the perspective of
the National Health Service (NHS) of the United Kingdom (U.K.) for
cost year 2018/19, adhering to contemporary practice guidelines and
the NICE reference case [9].2.3. Time horizon
The economic evaluation estimated the cost and quality-of-life
(QALY) gained, by trial arm, over the 1-year time horizon of the BHF
CorMicA trial.452.4. Discount rate
The discounting of NHS costs and health outcomes was not neces-
sary for the economic evaluation as the CorMicA trial was limited to a
1-year time horizon.
2.5. Conceptual model of the CorMicA trial
We developed a conceptual model to illustrate the clinical pathway
for each clinical strategy (Fig. 1).
The conceptualmodel beginswith a patientwith signs and/or symp-
toms of angina who has received coronary angiography and are subse-
quently diagnosed with no obstructive coronary artery disease
(NOCAD). At this point, the standard care procedure would end.
In line with the CorMicA trial, patients may then receive either a
“sham test” (control group) or the IDP (intervention group). In the con-
trol group branch of the model, patients receive the IDP but the results
are not disclosed to the attending clinicians who are therefore blind to
the IDP results. Patients then receive the standard of care for patients
with signs and/or symptoms of angina but no CAD.
In the intervention group branch of the conceptual model, patients
receive the IDP. Physicians were informed of the IDP results and were
able to revise their initial diagnosis, which was based on the angiogram
and all of the other available clinical information (e.g. prior non-invasive
test results, medical history). Based on this new information, patients
could either receive a diagnosis of positive or negative (for the purposes
of the conceptual model, a positive diagnosis for any of theMVA or VSA
endotypes is categorised as “positive”). Patients were then subse-
quently offered alternative medication and/or lifestyle modification ad-
vice depending on their revised diagnosis. If patientswere subsequently
diagnosed as “negative”, anti-anginal therapies were discontinued.
2.6. Resource use and cost analysis
Resource use estimates were obtained from the CorMicA trial, pub-
lished literature and expert opinion (the CorMicA clinical trial team)
(Table 1). Medication, participation in a cardiac rehabilitation pro-
gramme, and IDP costs were included in the base case analysis.
Anginal medications were measured at baseline, 6 months and 12
months in the trial. Based on these data, we measured the proportion
of the year a patient spent on each medication. We then estimated the
proportion of the year spent on each mediation by the mean patient
in each trial arm. Relevant unit costs were adjusted to annual costs for
eachmedication and attached to the time spent onmedication to obtain
the mean cost of medication by trial arm. The cost of the IDP was in-
cluded for all patients in the intervention group only. The unit cost of
a cardiac rehabilitation cost was attached to the number of patients
reporting attendance at a cardiac rehabilitation programme at 12
months. Medication cost, IDP test cost and cardiac rehabilitation pro-
gramme cost were combined to obtain a mean total patient cost by
trial arm.
All unit costs were collected or converted into UK pounds sterling
(£) for the price year 2018/19. Unit costs were collected from routine
sources such as the British National Formulary [10], Personal Social Ser-
vices Resource Unit (PSSRU) [11] and NHS Reference Costs [12]. Some
unit costs were obtained from NHS Reference Costs or from local
sources (NHS Golden Jubilee National Hospital) (Table 1).
2.7. Quality-of-life analysis
Quality-of-life (QoL) outcomes were based on the EuroQoL-5D (EQ-
5D-5L) questionnaire and collected at baseline, 6 and 12 months in the
CorMicA trial participants and expressed as health utility indices.
Quality adjusted-life years were calculated using the area-under-
the-curve method (AUC) [13]. The AUC was estimated for each
Fig. 1. Conceptual model of the clinical pathway associated the intervention and control group.
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ity measurement in the trial by their health utility value over that time
period.
2.8. Cost-effectiveness analysis
Mean cost and QALY gain per patient, by trial arm, was estimated by
using a generalized linearmodel (GLM) and adjusting for potential con-
founding factors (age, sex, BMI and trial arm). The appropriate familyTable 1
Resource use item and unit cost.
Medication Dose
Statin 40 mg daily
Beta-blocker 2.5 mg daily
Calcium channel blocker 120 mg daily
Isosorbide mononitrate 20 mg daily
Nicorandil 40 mg daily
ACE inhibitor 10 mg daily
Ranolazine 1000 mg daily
Ivabradine 14 mg daily
Nitroglycerin (spray) 1 bottle per 3 months
IDP (test) Resource use
Catheter lab time Per hour
Acetylcholine test Per vial
Adenosine Per vial
Diagnostic coronary guidewirea,b Per guidewire
Other costs Resource use
Cardiac rehabilitation programme Per programme
Re-presentation package of care (scenario analysis only) Resource us
Coronary angiogram Per test
GP appointment Per appointm
Cardiology outpatient appointment Per appointm
Blood test, U&E renal test, lipids test, Hba1c test Per test (one
a The diagnostic coronary guidewire used in this study was PressureWire X (Abbott Vascula
b One third of patients in the CorMicA trial had a guidewire in place prior to IDP. For this re
(rather than every patient).
46for the GLM was selected based on the results of the modified Park's
test. Our final cost model was based on the log link and gamma family
and our final QALY model was based on the identity link and Gaussian
family. There were few missing resource-use or EQ-5D data in the
CorMicA trial (≤5%). Where missing data existed, multiple imputation
by chained equations (MICE) was used to impute missing data [14].
All analyses were conducted using Stata 14 (StataCorp).
The outcomes of interest are mean costs, mean quality adjusted life











£400 NHS Golden Jubilee costing records
£7 BNF
£3 BNF
£350 NHS Golden Jubilee costing records
Unit cost Source
£279 NHS Reference costs
e Unit cost Source
£1379 NHS Reference costs
ent £37 PSSRU 2018
ent £134 PSSRU 2018
of each test) £7 NHS Reference costs
r, Santa Clara, CA).
ason, the cost of a guidewire is applied to two thirds of patients in the intervention group
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with awillingness-to-pay (WTP) threshold of £20,000 per QALY gained,
which is a commonly accepted cost-effectiveness threshold used by the
National Institute for Health and Care Excellence (NICE) in the United
Kingdom.
2.9. Sensitivity analysis
The distribution of incrementalmean costs andQALYs produced by a
bootstrap analysis were presented on the cost-effectiveness plane. Cost-
effectiveness acceptability curves (CEACs) were used to present the un-
certainty in the decision regarding themost cost-effective option, over a
variety of monetary willingness-to-pay threshold.
2.10. Scenario analyses
Data on the number of previous coronary angiograms among pa-
tients enrolled in the CorMicA trial indicated that approximately one
third (51 out of 151) of patients had “at least one previous coronary an-
giogram” [15]. This aligns with the experience of clinical experts in-
volved in both the trial, and in the routine care of this patient
population, which suggests that patients with signs and symptoms of
angina, but no obstructive coronary artery disease are liable to re-
present in primary or secondary care.
Given the large potential cost associated with these re-
representations, we modelled the impact of IDP testing on reducing
the proportion of patients re-presenting to primary and secondary
care with signs/symptoms of angina following coronary angiography.
To implement this scenario in the model, we assumed that patients di-
agnosed as negative for microvascular or vasospastic angina following
IDP testing did not re-presentwith suspected angina, and that a propor-
tion of patients in the control group do re-present. For patients who re-
present, we proposed a typical “package of care” associated with a re-
presentation, including: one coronary angiogram, three GP appoint-
ments, two cardiology outpatient appointments and standard care diag-
nostic tests (U&E, lipids, Hba1c). In the CorMicA trial, data on repeat
visits to primary care or hospital outpatient clinics were not prospec-
tively captured, as such there is some uncertainty as to the true impact
of adjunctive functional test in a real-world setting.
The unit costs associated with these resources are given in Table 1.
Based on the utilisation of each resource required, we estimated a cost
associated with an angiogram package of care of £1786. We estimated
the impact on the mean cost per patient in the control group if one
third, one fifth, and one tenth of patients re-present in primary care.
2.11. Ethical approval
TheWest of ScotlandResearch Ethics Committee approved the study
(REC 1 reference 16/WS/0192).
2.12. Patient and public involvement
CorMicA researchers engaged with the patient population (service
users) and the British Cardiovascular Care Partnership in the design of
the CorMicA trial.
3. Results
The baseline characteristics of the patient population are given in
Table 2. Themedian age in the studywas 61 years old, with themajority
of the study participants being female (73.5%). There was a high preva-
lence of cardiovascular risk factors. Participants had impaired quality of
life at baseline, as reflected by EQ-5D-5L health status (mean: 0.60, s.d.:
0.29) and SAQ Summary Score (mean 50.8, s.d.: 18.1).473.1. Resource use results
The mean time spent on medication was greater in seven out of the
nine medications included in the intervention group, compared with
the control group (Table 3). Thirty patients (40%) reported attending a
cardiac rehabilitation programme in the intervention group, compared
with 12 patients (16%) in the control group. All patients in the interven-
tion group received the IDP test, compared with none in the control
group.
3.2. Cost results
The total mean cost per patient in the control arm of the trial was
£103 andwas comprised solely of medication and cardiac rehabilitation
programme costs (Table 4). The total mean cost per patient in the inter-
vention group was £568 and was comprised of the costs of the IDP,
medication and cardiac rehabilitation programme. This equates to an in-
cremental cost of £465 at 12 months associated with the intervention
group.
3.3. Quality-of-life results
We estimated themeanQALY gain using the AUC approach. Patients
in the control group had amean QALY of 0.548 at 12months, compared
with 0.652 in the intervention group (Table 4). This equates to a mean
QALY gain of 0.104 at 12 months in patients in the intervention group.
3.4. Cost-effectiveness results
The incremental cost per QALY gained at 12 months was £4500
(£2937, £33264) (Table 4). Compared with a willingness-to-pay
(WTP) threshold of £20,000 per QALY, this suggest that the use of strat-
ified medicine with the IDP and linked medical therapy is a cost-
effective use of resources.
3.5. Sensitivity analysis
A visual illustration of the uncertainty surrounding the mean incre-
mental cost and QALY gain in the intervention group over 1000 itera-
tions of bootstrap analysis plotted on the cost-effectiveness plane is
presented in Fig. 2. The x-axis represents the incremental QALY gain,
and the y-axis represents the incremental cost, associated with the in-
tervention group compared with the control group. The majority of
the cost and QALY estimates are placed in the north-east quadrant of
the cost-effectiveness plane, suggesting that the use of the intervention
is associated with an incremental cost and incremental QALY gain.
The probability of the intervention being cost-effective, compared
with the control group, is given for alternative willingness-to-pay for
QALY gain thresholds in Fig. 3. At a WTP threshold of £20,000 per
QALY gained, there is a 96% probability of the intervention being cost-
effective, based on the uncertainty described by our bootstrap analysis.
3.6. Scenario analysis
We explored the impact on our cost-effectiveness results of making
an assumption regarding the number of re-presentations that might be
avoided as result of the introduction of stratifiedmedicine involving IDP
testing with linked therapy. Including the cost of re-presentations has
the impact of increasing the cost-effectiveness of the intervention, com-
pared with the base-case scenario (Table 5). A reduction in the propor-
tion of patients who re-present for angiograms has the impact of
reducing the cost-effectiveness associated with the intervention. How-
ever, for all re-presentation scenarios considered, the intervention was
still either highly cost-effective or cost-saving.
Table 2
Baseline demographic and clinical characteristics of the CorMicA patient population.
All (n = 151) Control (n = 76) Intervention (n = 75)
Age 61 (53, 68) 60 (53, 68) 62 (54, 69)
Female 111 (73.5%) 58 (76.3%) 53 (70.7%)
BMI (kg/m2) 29.7 (25.6, 34.7) 29.7 (25.6, 34.0) 29.6 (25.7, 34.8)
Smoker 27 (17.9%) 14 (18.4%) 13 (17.3%)
Previous myocardial infarction 24 (15.9%) 13 (17.1%) 11 (14.7%)
Previous stroke or TIA 20 (13.2%) 13 (17.1%) 7 (9.3%)
Diabetes mellitus 29 (19.2%) 15 (19.7%) 14 (18.7%)
Dyslipidaemia 120 (79.5%) 61 (80.3%) 59 (78.7%)
Family history of CVD 105 (69.5%) 51 (67.1%) 54 (72.0%)
Predicted 10-year CHD riska 18.6 (10.6, 31.4) 18.1 (9.7, 27.9) 19.0 (11.9, 38.9)
Aspirin 131 (86.8%) 67 (88.2%) 64 (85.3%)
Beta-blocker 101 (66.9%) 51 (67.1%) 50 (66.7%)
Calcium channel blocker 52 (34.4%) 28 (36.8%) 24 (32.0%)
Nitrates Statin 71 (47.0%) 38 (50.0%) 33 (44.0%)
Statin 126 (83.4%) 66 (86.8%) 60 (80.0%)
Nicorandil 26 (17.2%) 15 (19.7%) 11 (14.7%)
ACE inhibitor or angiotensin receptor blocker 68 (45.0%) 35 (46.1%) 33 (44.0%)
Total cholesterol (mmol/L) 3.55 (0.98) 3.57 (1.06) 3.52 (0.90)
HDL cholesterol (mmol/L) 1.2 (0.4) 1.2 (0.3) 1.2 (0.4)
Baseline angina questionnaire: non-angina
Definite (typical) angina 97 (64.2%) 42 (55.3%) 55 (73.3%)
Probable (atypical) angina 54 (35.8%) 34 (44.7%) 20 (26.7%)
Seattle angina questionnaire
Seattle Angina (summary) score 50.8 (18.1) 49.0 (17.2) 52.6 (18.9)
Angina limitation 52.1 (24.4) 52.4 (24.3) 51.9 (24.7)
Angina stability 44.7 (24.4) 41.4 (25.3) 48.0 (23.2)
Angina frequency 59.3 (23.5) 54.9 (21.3) 63.7 (25.0)
Angina treatment satisfaction 81.9 (19.5) 81.9 (20.0) 81.8 (19.1)
Angina quality of life 40.9 (21.7) 39.7 (21.7) 42.1 (21.9)
Quality of life (EQ5D-5L)
Index value 0.60 (0.29) 0.58 (0.30) 0.62 (0.28)
VAS score 66.3 (20.5) 67.9 (21.1) 64.6 (19.8)
Stress electrocardiogram (performed) 95 (62.9%) 46 (60.5%) 49 (65.3%)
Negative (normal) 13 (13.7%) 6 (13.0%) 7 (14.3%)
Inconclusive 37 (39.0%) 18 (39.1%) 19 (38.8%)
Abnormal 45 (47.4%) 22 (47.8%) 23 (46.9%)
Radionuclide myocardial perfusion (performed) 58 (38.4%) 30 (39.5%) 28 (37.3%)
Negative or inconclusive 28 (48.3%) 17 (56.7%) 11 (39.3%)
Abnormal 30 (51.7%) 13 (43.3%) 17 (60.7%)
Values are median (interquartile range), n (%), or mean +/− SD.
a ASSIGN risk score.
Table 3
Mean resource use (proportion and 95% confidence intervals) and mean cost (£), by trial arm.
Standard care with control Standard care with stratified medicine Standard care with control Standard care with stratified medicine
Resource use (proportion and 95% CIs) Mean cost per patient (£)
Medication
Statin 0.59 (0.50, 0.69) 0.79 (0.70, 0.89) 6.81 (5.77, 7.85) 9.157 (8.10, 10.21)
Beta-blockers 0.52 (0.44, 0.60) 0.58 (0.49, 0.66) 5.99 (5.04, 6.94) 6.67 (5.711, 7.63)
Nitroglycerin 0.34 (0.26, 0.41) 0.79 (0.71, 0.86) 4.11 (3.19, 5.02) 9.48 (8.55, 10.40)
Nicorandil 0.11 (0.04, 0.17) 0.15 (0.08, 0.21) 5.13 (2.18, 8.07) 6.80 (3.82, 9.79)
ACE 0.36 (0.26, 0.46) 0.51 (0.40, 0.61) 9.89 (7.22, 12.56) 13.69 (10.98, 16.40)
Ranolazine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 12.50 (0.00, 28.41) 7.28 (0.00, 23.40)
Ivabradine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 1.79 (0.00, 3.70) 0.90 (0.00, 2.83)
CCB 0.20 (0.11, 0.29) 0.42 (0.33, 0.52) 6.04 (3.32, 8.76) 12.60 (9.84, 15.35)
Isonitrate 0.26 (0.17, 0.35) 0.34 (0.25, 0.43) 9.59 (6.33, 12.84) 12.56 (9.27, 15.86)
Cardiac rehabilitation programme
12 (16%)⁎ 30 (40%)⁎ 43.53 (16.20, 70.66) 112.44 (86.15, 141.33)
IDP test
Catheter lab time 0 20 min 0 133
Acetylcholine test 0 1 vial 0 7
Adenosine 0 1 vial 0 3
Diagnostic coronary guidewire 0 Two thirds of patients 0 233
⁎ p-value (difference in proportion) = 0.001.
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Table 4
Mean costs, mean QALYs, and cost-effectiveness ratio (and 95% confidence intervals) for the intervention group and control group.
Cost analysis Mean medication cost (£) Cardiac rehab programme (£) IDP cost Total cost
Control group £61 (40, 81) £44 (21, 67) N/A £103 (77, 128)
Intervention group £80 (62, 98) £112 (80, 143) £376 (€410) £568 (419, 714)
Difference £19 (−8, 46) £68 (29, 107) £376 (€410) £465 (397, 530)
QALY analysis Mean QALY 95% confidence interval
Control group 0.548 0.488, 0.609
Intervention group 0.652 0.589, 0.714
Difference 0.104 0.018, 0.190
Cost-effectiveness results Incremental Costs (£) Incremental QALYs Incremental cost-effectiveness ratio (ICER) (£)
Control group
Intervention group £465 (397, 530) 0.104 (0.018, 0.190) £4500 (2937, 33264)
Fig. 2. Cost-effectiveness plane: incremental mean total costs and QALYs associated with
the intervention group.
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Our cost-effectiveness analysis of the CorMicA trial found that the in-
troduction of stratifiedmedicine, including an adjunctive interventional
diagnostic procedure for the management of patients with signs and
symptoms of angina when obstructive coronary artery disease is ex-
cluded by the angiogram, is likely to be associated with an increase in
patient quality-of-life and an increase in health-related resource useFig. 3. Cost-effectiveness acceptability curve (CEAC): probability of cost-effectiveness at
alternative WTP thresholds.
49over the trial period. With a mean incremental cost of £465 and incre-
mental QALY gain of 0.104 per patient, we estimate an incremental
cost-effectiveness ratio of £4500. Hence, our results find that stratified
medicine in this patient population and setting is likely to be cost-
effective in a UK setting.
The CorMicA trial participants had substantial impairment in
quality-of-life at baseline, as reflected by EQ-5D-5L health status [16]
and SAQ Summary Score [17,18]. Our results have provided insights
into the mechanisms of treatment effect. We have found that that the
benefit is determined to an appreciable extent by changes inmedication
aligned to the endotype. Other factors, such as participation in cardiac
rehabilitation and control of vascular risk factors, are also relevant.
The potential reduction in repeat coronary angiogram procedures
(and related cost saving) in patients with persisting symptoms of an-
gina, as a result of introducing IDP testing, has the potential to increase
the cost-effectiveness of IDP testing.
The burden of INOCA, particularly in women, is known to be signifi-
cant [19]. Three quarters of the trial participants were female. Cardiol-
ogy trials generally enrol more males than females, not least since
coronary artery disease predominately affects men. Accordingly,
CorMicA provides new data that is particularly relevant to heart disease
in women.
To date, there are no comparable studies. CorMicA was the first,
randomised controlled trial of stratified medicine in angina. INOCA in-
cludes a large sub-population, representing almost half of all-comers,
presents an unmet clinical need, that are usually discounted from clini-
cal trials. It is noteworthy that the health-related quality of life, as mea-
sured by EQ5D-5 L and SAQ scores, were lower in CorMicA (patients
with NOCAD), compared with recent clinical trials of patients with ob-
structive coronary artery disease (ORBITA [17], ISCHEMIA [18]).
This is the first study to investigate the health-related resource use
implications of the introduction of adjunctive coronary function testing
in patients with INOCA. There is no long-term evidence on the re-
presentation rate of patients with signs and symptoms of angina with
a negative diagnosis of macrovascular angina following coronary angi-
ography. In the CorMicA trial population, one in three patients had a his-
tory of prior coronary angiography indicating a persisting health burden
and related demand on primary and secondary care. This can be ex-
plained by the limitations of the standard, angiography-guided care to
reduce the health need of affected patients. The International Coronary
Microvascular Angina (iCorMicA) trial which will randomise 1500 pa-
tients in Europe, is designed to address this evidence gap in multiple
centres in different healthcare settings (ClinicalTrials.gov Identifier:
NCT04674449). However, scenario analysis of our results suggests
that, even when varying the proportion of patients expected to re-
present for angiograms, stratified medicine involving the IDP test is
still highly likely to represent a cost-effective use of resources. Indeed,
even if no patients re-present (base case results), this clinical strategy
is still likely to be cost-effective. In addition, our analysis included only
Table 5









Incremental cost-effectiveness ratio (ICER)
(£)
One third of patients re-present Control group £698 0.548
Intervention
group
£568 0.652 £-130 0.104 Dominated
One fifth of patients re-present Control group £460 0.548
Intervention
group
£568 0.652 £108 0.104 £1038
One tenth of patients re-present Control group £282 0.548
Intervention
group
£568 0.652 £286 0.104 £2750
R. Heggie, A. Briggs, B. Stanley et al. International Journal of Cardiology 337 (2021) 44–51costs attributable to theUKNHShealthcare system –wedid not attempt
to capture non-healthcare system costs, such as productivity costs (both
absenteeism and presenteeism). This cost to the individual and to soci-
ety from such loses has been shown to be significant [20].
The diagnostic management of stable chest pain is also evolving. CT
coronary angiography (CTCA) has very high sensitivity for coronary ar-
tery disease and moderately high specificity for discriminating obstruc-
tive lesions. CTCA is recommended as the first line test in patients
presenting with stable chest pain in the National Health Service [21]
and is increasingly adopted in Europe [22], including the United States
[23]. The functional significance of coronary artery lesions may be
assessed using adjunctive FFR-CT, however, since CTCA does not pro-
vide information on ischaemia (the metabolic consequence of angina),
the implications of this strategy for patients with INOCA are uncertain.
The CorCTCA trial is prospectively assessing this evidence gap and a
health economic analysis will also be undertaken [24].
The quality-of-life improvement in the intervention group is be-
lieved to be a result of both pharmacological and non-pharmacological
factors, including participation in cardiac rehabilitation. The IDP iden-
tifies INOCA in patientswho otherwisewould have received a false neg-
ative diagnosis and ineffective treatment. Our results suggest that the
benefit is determined to an appreciable extent by changes inmedication
aligned to the endotype. Other factors, such as participation in cardiac
rehabilitation and control of vascular risk factors, are also relevant. Fur-
ther research aimed at understanding the mechanism by which this
quality-of-life increase is generated seems warranted.5. Conclusion
We undertook an economic evaluation of the CorMicA trial to esti-
mate the cost-effectiveness of introducing stratified medicine using an
adjunctive interventional diagnostic procedure with mechanistically-
targeted medical therapy for the management of patients with signs
and symptoms of angina. Our results suggest that the introduction of
this clinical strategy is likely to be cost-effective. The economic benefits
of IDP testing increase further if we incorporate plausible assumptions
regarding repeat angiograms in patients with persistent sign/symptoms
of angina.Source of funding
This work was funded by a British Heart Foundation grant (PG/17/
25/32884, RE/13/5/30177, and RE/18/6/34217).Data availability
The data underlying this article will be shared on reasonable request
to the corresponding author.50Contributorship statement
All authors were involved in drafting the article or revising it criti-
cally for important intellectual content, and also for final approval of
the version to be published. RH, A.B, T.F and C·B also made substantial
contributions to the conception and design, acquisition of data, or anal-
ysis and interpretation of data. C.B is responsible for the overall content
of the CorMicA trial and associated outputs.
Declaration of competing interest
A.B., B.S., R.G., H.E., A.S., M.M.L., S.H., E.Y., R.McD. have no relevant
disclosures. C·B. is employed by the University of Glasgow which holds
consultancy and research agreements with Abbott Vascular,
AstraZeneca, Boehringer Ingelheim, Coroventis, GSK, HeartFlow,
Menarini, Neovasc, and Siemens Healthcare. K.G.O. has received consul-
tant and speaker fees from Abbott Vascular and Boston Scientific. He is
employed by Biosensors. S.W. has received consultant and speaker fees
from Boston Scientific. P.R. has received consultant and speaker fees
from Astra Zeneca. K.R has received educational support from Abbott
Vascular and speaker fees from Astra Zeneca. RMT has acted as an advi-
sor for Novartis. MMEhas a proctoring agreementwith Boston Scientific
and Vascular Perspectives. T.F. and DC have received speakers fees from
Abbott Vascular.
Acknowledgments
The authors acknowledge the patients, the staff members, and the
British Heart Foundation, who supported this study. We thank the trial
clinical events committee including Dr. Andrew Hannah and Dr.
Andrew Stewart, Aberdeen Royal Infirmary.
References
[1] S. Cook, A.Walker, O. Hugli, M. Togni, B. Meier, Percutaneous coronary interventions
in Europe: prevalence, numerical estimates, and projections based on data up to
2004, Clin. Res. Cardiol. 96 (2007) 375–382.
[2] M.R. Patel, E.D. Peterson, D. Dai, M. Brennan, R. Redberg, V. Anderson, et al., Low di-
agnostic yield of elective coronary angiography, N. Engl. J. Med. 362 (2010)
886–895.
[3] T. Ford, B. Stanley, R. Good, P. Rocchiccioli, M. McEntegart, S. Watkins, et al., Strati-
fied medical therapy using invasive coronary function testing in angina, J. Am.
Coll. Cardiol. 72 (23 Part A) (2018 Dec) 2841–2855.
[4] T.J. Ford, D. Corcoran, C. Berry, Stable coronary syndromes: pathophysiology, diag-
nostic advances and therapeutic need, Heart 104 (2018) 284–292.
[5] G. Montalescot, U. Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, et al.,
2013 ESC guidelines on the management of stable coronary artery disease: the
Task Force on the management of stable coronary artery disease of the European
Society of Cardiology, Eur. Heart J. 34 (2013) 2949–3003.
[6] T.J. Ford, D. Corcoran, K.G. Oldroyd, M. McEntegart, P. Rocchiccioli, S. Watkins, et al.,
Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular
Angina (CorMicA) stratified medicine clinical trial, Am. Heart J. 201 (2018) 86–94,
https://doi.org/10.1016/j.ahj.2018.03.010.
[7] T. Ford, B. Stanley, N. Sidik, R. Good, P. Rocchiccioli, M. McEntegart, et al., 1-year out-
comes of angina management guided by invasive coronary function testing
(CorMicA), J. Am. Coll. Cardiol. Intv. 13 (1) (2020 Jan) 33–45.
R. Heggie, A. Briggs, B. Stanley et al. International Journal of Cardiology 337 (2021) 44–51[8] Henry A. Glick, Jalpa A. Doshi, Seema S. Sonnad, Daniel Polsky, Economic Evaluation
in Clinical Trials. OUP Catalogue, Oxford University Press, 2007 number
9780198529972.
[9] NICE, Guide to the Methods of Technology Appraisal, Available at www.niceorguk/
process/pmg9/chapter/the-reference-case 2013 Accessed on 2nd September 2020.
[10] J.F. Committee, British National Formulary (online), BMJ Group and Pharmaceutical
Press, London, 2020 , Available at www.medicinescomplete.com Accessed on 2nd
September 2020.
[11] Personal Social Services Research Unit (PSSRU), Available at https://www.pssru.ac.
uk/ Accessed on 2nd September 2020.
[12] National Schedule of Reference Costs, Available at https://improvement.nhs.uk/re-
sources/reference-costs/ 2017/18 Accessed on 2nd September 2020.
[13] A. Manca, N. Hawkins, M. Sculpher, Estimating mean QALYs in trial-based cost-
effectiveness analysis: the importance of controlling for baseline utility, Health
Econ. 14 (5) (2005) 487–496.
[14] S. Ramsey, R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla, et al., Good research
practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA
Task Force report, Value Health 8 (5) (2005 Sep-Oct) 521–533, https://doi.org/10.
1111/j.1524-4733.2005.00045.x16176491.
[15] T.J. Ford, E. Yii, N. Sidik, R. Good, P. Rocchiccioli, M. McEntegart, et al., Ischemia and
no obstructive coronary artery disease: prevalence and correlates of coronary
vasomotion disorders, Circ. Cardiovasc. Interv. 12 (12) (2019), e008126, .
[16] A. Szende, B. Janssen, J. Cabases, Self-Reported Population Health: An International
Perspective Based on EQ-5D [Internet], Springer, Dordrecht (NL), 2014 PMID:
29787044.
[17] R. Al-Lamee, D. Thompson, H.M. Dehbi, S. Sen, K. Tang, J. Davies, et al., Percutaneous
coronary intervention in stable angina (ORBITA): a double-blind, randomised con-
trolled trial, Lancet 391 (10115) (2018 Jan 6) 31–40, https://doi.org/10.1016/
S0140-6736(17)32714-9.51[18] J.A. Spertus, P.G. Jones, D.J. Maron, S.M. O’Brien, H.R. Reynolds, Y. Rosenberg, et al.,
Health-status outcomes with invasive or conservative care in coronary disease, N.
Engl. J. Med. 382 (15) (2020 Apr 9) 1408–1419, https://doi.org/10.1056/
NEJMoa1916370.
[19] L.J. Shaw, C.N. Merz, C.J. Pepine, S.E. Reis, V. Bittner, K.E. Kip, et al., Women’s Ische-
mia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in
women with suspected ischemic heart disease: results from the National Institutes
of Health – National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia
Syndrome Evaluation, Circulation 114 (9) (2006 Aug 29) 894–904, https://doi.org/
10.1161/CIRCULATIONAHA.105.609990 Epub 2006 Aug 21. PMID: 16923752.
[20] C.L. Schumann, R.C. Mathew, J.L. Dean, Y. Yang, P.C. Balfour Jr., P.W. Shaw, et al.,
Functional and economic impact of INOCA and influence of coronary microvascular
dysfunction, JACC Cardiovasc. Imaging (2021 Apr 7) https://doi.org/10.1016/j.jcmg.
2021.01.041 S1936-878X(21)00179-0. Epub ahead of print. PMID: 33865784.
[21] NICE, Recent-Onset Chest Pain of Suspected Cardiac Origin: Assessment and Diagno-
sis, Clinical guideline [CG95]. Available at https://www.nice.org.uk/guidance/CG95
Accessed on September 2nd 2020.
[22] J. Knuuti, W. Wijns, A. Saraste, D. Capodanno, E. Barbato, C. Funck-Brentano, et al.,
2019 ESC Guidelines for the diagnosis and management of chronic coronary syn-
dromes, Eur. Heart J. 41 (3) (2020) 407–477, https://doi.org/10.1093/eurheartj/
ehz425.
[23] M. Poon, J. Lesser, C. Biga, ESC Guidelines for the diagnosis and management of
chronic coronary syndromes, Eur. Heart J. 41 (3) (2020 Jan 14) 407–477, https://
doi.org/10.1093/eurheartj/ehz425.
[24] N.P. Sidik, M. McEntegart, G. Roditi, T.J. Dord, M. McDermott, A. Morrow, et al., Ra-
tionale and design of the British Heart Foundation (BHF) coronary microvascular
function and CT Coronary Angiogram (CorCTCA) study, Am. Heart J. 221 (2020)
48–59, https://doi.org/10.1016/j.ahj.2019.11.015.
